A Phase I Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of HIV-1 Recombinant Envelope Glycoprotein gp160

NCT00000745 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

72

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Hepatitis B Vaccine (Recombinant)
BIOLOGICAL: gp160 Vaccine (MicroGeneSys)

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Collaborators

[object Object]